Product designers are embracing how users actually feel after years of pushing flat and sleek
5 min
The tyranny of touch screens may be coming to an end.
Companies have spent nearly two decades cramming ever more functions onto tappable, swipeable displays. Now buttons, knobs, sliders and other physical controls are making a comeback in vehicles, appliances and personal electronics.
In cars, the widely emulated ultra-minimalism of Tesla’s touch-screen-centric control panels is giving way to actual buttons, knobs and toggles in new models from Kia , BMW ’s Mini, and Volkswagen , among others. This trend is delighting reviewers and making the display-focused interiors of Tesla and its imitators feel passé.
Similar re-buttonisation is occurring in everything from e-readers to induction stoves.
Perhaps the most prominent exponent of this button boom is the company that set us lurching toward touch screens in the first place. Apple added a third button it calls the “action button” to its full slate of new iPhone 16s unveiled this month, after introducing the feature on its upscale Apple Watch Ultra and Pro-model iPhones over the past couple of years. It also added a button-like “camera control” input on the iPhone’s side.
As Apple shows, companies aren’t just rediscovering buttons, they’re reconceiving them. The camera control includes touch features, and the company has also developed the “force sensor” that enables its AirPods to respond when you squeeze their stems.
Engineers and industrial designers—often prodded by user complaints—are tapping into our exquisitely sensitive sense of touch and spatial awareness, known as proprioception. And it’s all in service of making gadgets easier, more fun and, in some cases, safer to use. We want to touch type or operate cruise control without averting our eyes from the road.
To understand why buttons are making a comeback in a world in which any kind of controls are possible, it helps to understand how we got to the current, too-often sorry state of human-machine interfaces.
Touch screens have their virtues, which explains the initial enthusiasm for them. We can do a lot more by tapping our iPhones than we ever could have with the old-school BlackBerry , however much we miss those clicky little keyboards.
As soaring production drove down the price of such displays, though, they became something of a crutch for gadget designers and corporate bean counters.
“Now that touch screens are the cheapest option, they’re being deployed everywhere, even in places where they don’t belong,” says Sam Calisch, chief executive of Copper, a startup that makes induction ranges for cooking . In electric stoves and ovens, this has led to poor design decisions—for example, induction cooktops with touch-based controls that become inoperable when a pot boils over, as my Wall Street Journal colleague Nicole Nguyen lamented last year .
Even when our devices have buttons, they are too often the kind that are flat like touch screens, and have similar shortcomings. Capacitive buttons sit flush on hard surfaces and don’t actually give way when you press, and so can only signal they’ve been activated through sound or light. These, too, have taken over because they are cheap and easy to incorporate into the printed circuit boards that are already inside gadgets, whereas incorporating physical switches means additional wiring and complexity, Calisch says.
Anyone who has known the agony of having to mash a capacitive button on a newer washer, dryer or dishwasher knows how uniquely infuriating such cost-cutting measures—masquerading as futuristic interfaces—can be.
Fundamentally, the problem with touch-based interfaces is that they aren’t touch-based at all, because they need us to look when using them. Think, for example, of the screen of your smartphone, which requires your undivided gaze when you press on its smooth surface.
As a result, “touch screen” is a misnomer, says Rachel Plotnick, associate professor of cinema and media studies at Indiana University Bloomington, and author of the 2018 book “Power Button: A History of Pleasure, Panic, and the Politics of Pushing,” the definitive history of buttons. Such interfaces would be more accurately described as “sight-based,” she says.
The hazards of burying many of a vehicle’s controls inside touch-screen menus that need drivers to look at them have become so obvious that the one European automotive safety body has declared that vehicles must have physical switches and buttons to receive its highest safety rating. Responding to criticism from drivers, Volkswagen has pledged to bring back physical controls for certain oft-used features, such as climate control.
Newer electric vehicles from BMW Mini are bristling with physical controls. To make it so drivers never have to take their eyes off the road, industrial designers at Mini put into their vehicles a user-customizable head-up display that drivers can navigate using buttons and a scroll wheel on the steering wheel, says Patrick McKenna, head of product and marketing at Mini USA. These controls can also be accessed through the vehicle’s round touch screen, and via a voice assistant. The entire point of the vehicle’s interfaces is redundancy, safety and a reduction in distractions, he adds.
The switch back to physical interfaces is also, in many ways, a vibe shift. With touch screens ubiquitous, what was once viewed as luxurious is becoming tacky. Physical controls, done well, now signal the kind of thoughtfulness and exclusivity once attached to the original iPhone.
Take the knobs on the induction range from Copper. Made of walnut, they let cooks know, without looking, the level of heat they’ve set a burner to—just like physical knobs on a gas range. This is deliberate, says Calisch, who admits that in the past he’s put capacitive-touch sensors on other electronics he’s designed.
Physical controls are effective in part because of our sixth sense, known as proprioception. Distinct from the sense of touch, proprioception describes our innate awareness of where our body parts are. It is the reason we can know the position of all our limbs in three-dimensional space down to the precise position of the tips of our fingers.
Making good physical interfaces isn’t just about the utility of engaging our sense of touch; the big button comeback is also about joy. Think of the satisfying heft of the volume knob on a hi-fi stereo, or the way a proper ergonomic keyboard can make typing seem less of a chore.
A good example of this sense of fun is the hand crank on the side of the Playdate portable video game system, which also includes a familiar, plus-shaped D-pad and two buttons. Putting a controller that works like the crank on an old coffee grinder onto a gadget resembling the original Gameboy is about whimsy, but also introduces new game mechanics that would otherwise be cumbersome or even impossible on other devices, says Greg Maletic, director of special projects at Panic, the company that makes the Playdate.
Makers of musical instruments have always understood the importance of physical controls. Teenage Engineering, the Swedish consumer-electronics company Panic partnered with to make the Playdate, makes a variety of synthesisers bristling with a dizzying array of buttons, sliders and knobs.
Once you know what to look for, it becomes apparent that this kind of design thinking is showing up all over the place, and that adding physical controls back to a device ignominiously stripped of them can unlock new kinds of interaction and utility.
E-readers have begun adding back page-turn buttons. While Amazon has abandoned such buttons in its Kindles, competitors from Kobo, Nook and Boox all now offer models that include them.
Similarly, Apple—whose 2007 launch of the iPhone ushered in a touch-screen era—is adding a surprising variety of buttons back to devices that previously seemed on a trajectory to have none at all.
It restored the physical function keys atop the keyboards on its MacBook Pro computers in 2021, after replacing them with much fanfare in 2016 with a touch-screen strip that it touted as the Touch Bar. Apple boasted that restoring physical keys brought “back the familiar, tactile feel of mechanical keys that pro users love.”
The push to re-physicalise interfaces has even led to an unexpected side gig for Dr. Plotnick, the academic authority on buttons. Companies are tapping her to consult on how to improve their physical controls. At its heart, these consultations—which include advising on the function of potentially lifesaving buttons on medical devices—are about making interactions with machines less intimidating and more intuitive.
“You know, there’s often a lot of skill behind button pushing—even though it seems like the simplest thing in the world,” she says.
Copyright 2020, Dow Jones & Company, Inc. All Rights Reserved Worldwide. LEARN MORE
Following the successful launch of its Palais Collection, MAISON de SABRÉ has unveiled a new modular handbag system offering more than 720 styling combinations.
Automobili Lamborghini and Babolat have expanded their collaboration with five new colourways for the ultra-exclusive BL.001 racket, limited to just 50 pieces worldwide.
As millions flock to GLP-1s, doctors warn the drugs can cause rapid and significant muscle loss.
5 min
Chanel Robinson achieved exactly what the gold rush of blockbuster weight-loss drugs promised: She lost nearly 100 pounds, lowered her cholesterol to normal levels and reined in her polycystic ovary syndrome.
Yet, nearly three years into her journey on Mounjaro, the 30-year-old from Atlanta, Ga., is discovering the hidden costs of the slimmed-down life.
Robinson experiences muscle fatigue daily, feeling physically weak, frail and often cold. Robinson said she experiences bursts of sluggishness sporadically during the day, and has trouble with basic tasks like opening a jar. “It shouldn’t be this difficult,” she said.
GLP-1 drugs like Ozempic, Mounjaro and Zepbound have been a success for public health and the pharmaceutical companies that make them. Obesity rates are falling, the volume of food consumed in America is declining and retailers report a slump in sales of plus-size apparel. It has improved health and happiness for millions of people.
But for at least some of the 13 million Americans taking them, losing muscle along with fat is an unexpected downside that isn’t broadly discussed or immediately apparent.
The drugs can cause rapid and significant loss of lean muscle mass, up to 10%, comparable to a decade or more of aging, according to an analysis published by the American Diabetes Association.
The loss of lean tissue is similar to weight loss from dieting, but the magnitude over a short period can lead to frailty, instability and lack of coordination, doctors and researchers say. Another concern is that losing muscle could slow down patients’ metabolism, leading to weight regain.
“We are curing obesity by encouraging frailty,” said Daniel Green, principal research fellow at the University of Western Australia, who contributed to the analysis. Many taking weight-loss medications initially lose fat and feel great, but quickly start to feel weak and lethargic, he said.
Green’s research showed that the rate of muscle loss could be slowed significantly by regular strength workouts. “It should say ‘must be taken with resistance training’ on the box,” he said.
Drugmakers say weight-loss drugs should be taken only on the advice of a physician and as part of a long-term plan that includes diet and exercise.
A spokesperson for Eli Lilly, maker of Zepbound, said Food and Drug Administration guidelines say it should be used “with increased physical activity.” The spokesperson added: “Sustainable weight loss is about more than a number on a scale.”
Both Eli Lilly and Novo Nordisk said clinical trials showed users did lose some lean muscle tissue, though at far lower rates than fat. Liz Skrbkova, a spokeswoman for Novo Nordisk, said that trials for its drug Wegovy showed changes in muscle mass didn’t “significantly differ” from patients who took a placebo. Eli Lilly said users lost three times more fat weight than lean tissue.
Rayna Kingston, 30, from Denver, said her injections of Zepbound left her feeling so tired the following day that she struggled to complete anything other than basic tasks. She said she shifted her dose to a Sunday because Mondays were her least busy day. Her partner would bring her meals in bed because she felt so weak.
She stopped exercising, and said her doctor didn’t give her any guidance on strength training or muscle maintenance. “I was relying on Reddit forums to understand what was happening to my body,” she said. She got so frustrated with the fatigue she came off the medication just under two months later.
Experts say that losing muscle at such a rate can be especially dangerous for those over 50 or with osteoporosis or limited mobility as it could lead to an increased risk of injury. “Loss of muscle mass is detrimental to moving around and quality of life, but it is also not safe,” said Katsu Funai, associate professor at the University of Utah.
Elderly Americans are set to be able to get GLP-1s from Medicare from July.
There is also pushback from doctors and regulators against using weight-loss drugs as a “quick fix” to lose a bit of weight.
People who take GLP-1s regain weight four times faster than those who lose weight through lifestyle interventions, and weight regained is often mostly fat, according to a recent analysis published in the British Medical Journal. There currently are few, if any, guidelines or studies on de-prescribing the drugs, researchers say.
The nurse practitioner who prescribed Robinson the medication didn’t warn her that resistance training is essential to maintaining muscle mass, Robinson said. She said she regrets not exercising and now does Pilates once a week.
In the haste to disrupt the obesity epidemic, weight loss has been treated as the singular, undisputed metric of success, which experts say is problematic.
“People worship body weight as an outcome measure because it’s simple, quick and inexpensive,” said Green. “But what matters is fat and muscle mass, which is more expensive to measure as it requires an MRI.”
Grace Parkin, 34, a property manager from Sheffield, England, has lost 125 pounds after she started taking Mounjaro in 2024. “I don’t care about my muscle mass as long as I’m a healthy weight,” she said.
The doctor who prescribed the drug didn’t tell her to exercise, though the pharmacy that sold the medication gave her information on exercise and protein intake, she said.
She didn’t exercise and said she soon felt side effects: a “deathly cold, from the inside” likely because of the drug. Still, she vowed to keep going, saying the weight loss was worth it.
In response to some of the side effects, drug companies are hoping to develop weight-loss treatments aimed at preserving or even building lean muscle mass.
German drugmaker Boehringer Ingelheim recently said it had promising results from one such drug. Eli Lilly last September halted a trial of a similar drug.
While weight-loss medications are designed as lifelong treatments for chronic diseases, namely obesity and Type 2 diabetes, they are increasingly marketed as lifestyle fixes.
Tennis superstar Serena Williams, who used GLP-1s to slim down after having children, was featured in this year’s Super Bowl commercial promoting telehealth company Ro’s weight-loss medication.
Serena Williams poses for an ad campaign for a weight-loss drug. Ro/Handout/Reuters
Women may be particularly vulnerable to the drugs’s side effects, which can also include nausea, diarrhea, migraines and rarer cases of pancreatitis.
A study last year from a university hospital in Turin, Italy, showed that women are more prone to adverse reactions to weight-loss drugs than men, including muscle loss.
Green, the researcher, said the issue is of particular concern to those taking GLP-1s recreationally and who don’t have much muscle mass to begin with. Others say a lack of oversight is compounding the issue.
“Patients are self-reporting, and telehealth companies don’t have the patient in front of them to conduct a proper medical assessment,” said Rupal Mathur, an internist in Houston whose practice specializes in weight loss.
She said medical spas are prescribing off-label drugs that don’t meet the criteria set out by the FDA that justify a prescription.
The number of people taking weight-loss drugs who are not living with obesity or Type 2 diabetes is difficult to track since it is unregulated.
However, an analysis by the FDA from 2023 found that more than half of new Ozempic and Mounjaro users didn’t have Type 2 diabetes.
Scientists are calling for more clinical trials to pin down the full effects of weight-loss drugs on muscle loss in different demographics.
“The only studies that have been done have looked at people living with obesity or Type 2 diabetes,” said Green. “That makes it all the more concerning for those using weight-loss drugs in an ad hoc or unregistered way.”
